Antibody Response to Severe Acute Respiratory Syndrome‐Coronavirus‐2 Messenger RNA Vaccines in Liver Transplant Recipients

Alexandra T. Strauss, Andrew M. Hallett, Brian J. Boyarsky, Michael T. Ou, William A. Werbel, Robin K. Avery, Aaron A. R. Tobian, Allan B. Massie, James P. A. Hamilton, Jacqueline M. Garonzik‐Wang, Dorry L. Segev – 17 August 2021

Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers

Mansi Arora, James M. Bogenberger, Amro M. Abdelrahman, Jennifer Yonkus, Roberto Alva‐Ruiz, Jennifer L. Leiting, Xianfeng Chen, Pedro Luiz Serrano Uson Junior, Chelsae R. Dumbauld, Alexander T. Baker, Scott I. Gamb, Jan B. Egan, Yumei Zhou, Bolni Marius Nagalo, Nathalie Meurice, Eeva‐Liisa Eskelinen, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Kenneth H. Buetow, Mohamad B. Sonbol, Aaron S. Mansfield, Lewis R. Roberts, Tanios S. Bekaii‐Saab, Daniel H. Ahn, Mark J. Truty, Mitesh J. Borad – 17 August 2021

Monitoring of Donor‐Derived Cell‐Free DNA by Short Tandem Repeats: Concentration of Total Cell‐Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation

Esther Fernández‐Galán, Celia Badenas, Constantino Fondevila, Wladimiro Jiménez, Miquel Navasa, Joan Anton Puig‐Butillé, Mercè Brunet – 17 August 2021 – Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis of acute rejection (AR). Recently, donor‐derived cell‐free DNA (ddcfDNA) has emerged as a noninvasive biomarker to assess graft integrity.

Graft Survival and Segment Discards Among Split‐Liver and Reduced‐Size Transplantations in the United States From 2008 to 2018

John R. Montgomery, Alexandra Highet, Craig S. Brown, Seth A. Waits, Michael J. Englesbe, Christopher J. Sonnenday – 17 August 2021 – Split‐liver transplantation has allocation advantages over reduced‐size transplantation because of its ability to benefit 2 recipients.

Novel Composite Endpoint for Assessing Outcomes in Liver Transplantation: Arterial and Biliary Complication–Free Survival

Eric Savier, Yann De Rycke, Chetana Lim, Claire Goumard, Geraldine Rousseau, Fabiano Perdigao, Pierre Rufat, Chady Salloum, Laura Llado, Emilio Ramos, Josefina Lopez‐Dominguez, Alba Cachero, Joan Fabregat, Daniel Azoulay, Olivier Scatton – 16 August 2021 – Transplant and patient survival are the validated endpoints to assess the success of liver transplantation (LT). This study evaluates arterial and biliary complication–free survival (ABCFS) as a new metric.

Subscribe to